Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The ADAURA adjuvant randomized trial demonstrated that osimertinib prolonged DFS. It has now been reported that health-related quality of life (HRQoL) was not adversely affected by adjuvant osimertinib. Does this mean that adjuvant osimertinib should now be standard as we await survival results? See related article by Majem et al., p. 2286.

Keyphrases

small cell lung cancer
early stage
advanced non small cell lung cancer
epidermal growth factor receptor
brain metastases
sentinel lymph node
tyrosine kinase
neoadjuvant chemotherapy
free survival